Lingering Shadows: The New York Times Explores Post-SSRI Sexual Dysfunction
A recent article in the New York Times titled “After Antidepressants, a Loss of Sexuality” brought a rarely discussed side effect of antidepressants to light: Post-SSRI sexual dysfunction (PSSD). The piece, written by Azeen Ghorayshi, delves into the experiences of individuals struggling with long-term sexual problems after discontinuing Selective Serotonin Reuptake Inhibitors (SSRIs), the most commonly prescribed type of antidepressant.
The article details the devastating impact PSSD can have on patients. Symptoms like genital numbness and anorgasmia disrupt not only sexual function but also the ability to form and maintain intimate relationships. While sexual dysfunction is a recognized side effect of SSRIs, the discussion often centers around temporary issues while on the medication. Ghorayshi’s piece sheds light on the under-reported phenomenon of these problems persisting even after stopping the drug.
The article acknowledges the complexity of the issue. Depression itself can cause sexual problems, making it difficult to isolate the cause. Additionally, a lack of research on long-term SSRI effects hinders our understanding of PSSD’s prevalence and mechanisms. This creates challenges for both patients and doctors, with some psychiatrists attributing the problems to underlying depression rather than the medication.
“After Antidepressants, a Loss of Sexuality” highlights the urgent need for more research on PSSD. Understanding the causes and developing treatment options is crucial for those living with this condition. The article also underscores the importance of open communication between patients and doctors. Discussing potential side effects, including PSSD, allows for informed decisions about treatment options and helps manage expectations.
While the path forward is uncertain, Ghorayshi’s piece is a step towards greater awareness. By bringing PSSD into the open conversation, the article empowers individuals to seek help and advocates for further research to bring relief to those living in the lingering shadows of antidepressant use.
It is clear that exercise, good diet and other lifestyle changes are far more effective than antidepressants which work in less than 20% of patients. That number may be skewed because the studies are conducted by the pharmaceutical companies.